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Erythropoietin and renal transplantation. The advent of eryth- THE IMPACT OF rHuEPO TREATMENT
ropoietin (rHuEPO) has revolutionized the treatment of ane- ON ALLOSENSITIZATION
mia in end-stage renal disease. While many studies indicate
The development of allosensitization is a common oc-beneficial effects of rHuEPO in hemodialysis, peritoneal dial-
currence in patients awaiting renal transplantation, withysis and predialysis patients, the impact of the drug in renal
transplantation is less clear. Treatment with rHuEPO may re- high levels (more than 50%) of panel reactive antibodies
duce the degree of allosensitization produced by random blood (PRA) being found in more than 20% of patients
transfusion while still allowing the possibility of the transplant awaiting transplant in most series [6]. The development
survival benefit derived from deliberate transfusion. Recovery of broadly reactive antibodies against human lympho-
from anemia post-transplantation is hastened by treatment
cyte antigens (HLA) class I identifies patients at highwith rHuEPO, while patients with failing allografts respond to
risk for renal allograft rejection [7]. Such patients alsorHuEPO in a fashion similar to dialysis patients, despite the
have poorer initial and one-year graft survival than theirconcomitant use of immunosuppressives. The erythropoietic
response to rHuEPO is abrogated during episodes of acute nonsensitized counterparts and have inferior long-term
rejection, and restored when successful treatment of rejection graft outcomes [7]. The causes of allosensitization in-
has occurred. Iron therapy is a critical factor for support of clude previous renal transplant and prior pregnancy, but
erythropoiesis and prevention of absolute iron deficiency post- the single most important cause is the number of prior
transplantation. In patients presenting for renal transplant, the
blood transfusions. Opeltz et al indicated that the inci-balance of evidence suggests that there is no increase in the
dence of allosensitization in patients receiving more thanrate of delayed graft function, graft loss or vascular thrombosis
20 units of blood was close to 30% in a study of approxi-for patients who had received prior rHuEPO therapy.
mately 737 patients awaiting cadaveric renal transplant
[8]. In addition, it has been reported that continued blood
transfusion is the most important cause of high PRA
The availability of recombinant human erythropoietin levels [9].
(rHuEPO) has revolutionized the care of patients with The use of recombinant human erythropoietin
anemia related to end-stage renal disease. Numerous (rHuEPO) for treatment of anemia prior to renal trans-
studies have highlighted the benefits of rHuEPO in pa- plant has been shown to eliminate almost completely
tients on hemodialysis and peritoneal dialysis, as well as the need for blood transfusion [10]. Avoidance of blood
suggested the relative safety and efficacy of therapy in transfusion would be expected to eliminate that compo-
predialysis patients [1–5]. The role of rHuEPO in renal nent of HLA sensitization that is transfusion related. It is
allograft patients is, however, less clear. There are a to be expected, therefore, that the percentage of patients
number of distinct areas in which treatment with presenting for transplant with a high PRA should be on
rHuEPO might have an impact on renal transplant pa- the decline. In addition, if continued transfusion is a
significant factor in the maintenance of high PRA, thentients. These include the potential for rHuEPO treat-
the elimination of transfusion should permit a progres-ment prior to transplant to reduce the degree of allosen-
sive decline in PRA levels among sensitized patients.sitization, with a subsequent impact on transplant
Several studies have suggested that PRA levels do in-outcome, the impact of prior rHuEPO therapy on the
deed fall in sensitized patients whose transfusion require-risks of renal transplant itself, and the role of rHuEPO
ments are eliminated by treatment with rHuEPO [11, 12].treatment both before and after transplant on the course
Others have failed to find such an association, perhapsof post-transplant anemia.
because the duration of follow-up has been too short
to identify a fall in levels of long-lived antibodies [13].
Ettenger, Marik and Grimm noted significant decreasesKey words: anemia, end-stage renal disease, erythropoiesis, allosensiti-
zation, rHuEPO. not only in total sensitization of patients during rHuEPO
therapy, but also in the titer of anti-HLA antibodies in 1999 by the International Society of Nephrology
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individual patients who did not experience a significant patients transplanted in their center [18]. Approximately
50% of patients had received rHuEPO. Delayed graftdecline in overall PRA [14]. It thus seems probable that
therapy with rHuEPO for renal anemia in the pretrans- function was significantly more common in rHuEPO-
treated patients (41% vs. 18%; P , 0.05), but thereplant patient can reduce or eliminate a significant portion
of the allosensitization that occurs, with a potential bene- were no differences between groups in the subsequent
incidence of acute rejection, time to first rejection orfit in both short- and long-term graft outcome.
Paradoxically, blood transfusion has also been known one-year graft, or patient survival.
Despite these concerns, data from transplant registriesfor many years to enhance graft outcome in renal allo-
graft recipients. Although the precise mechanism re- suggest that erythropoietin has little or no impact on
graft outcome. For example, in Canada, where nearlymains unclear, there is no doubt that renal transplant
outcome is better in transfused than nontransfused recip- 70% of both hemodialysis and continuous ambulatory
peritoneal disease patients receive rHuEPO prior toients [6]. The strength of the “transfusion effect” was a
15% to 20% increase in one-year graft survival in the transplant, the one-year graft survival rate has shown
continuous improvement from the period of 1981 toprecyclosporine era [6]. Since the advent of cyclosporine,
it has been progressively more difficult to discern a posi- 1995, including continued improvement over the period
from 1991 onward when rHuEPO entered widespreadtive benefit of blood transfusion on graft outcome, al-
though it has recently been reported that a positive bene- use in Canada [19]. Over the same period, 1981 to 1995,
only 157 of 3020 graft losses (5.2%) were attributed tofit of approximately 5% in one-year graft survival is still
evident for recipients of poorly matched (less than three either primary nonfunction or vascular thrombosis, and
there has been no evidence for an increased trend toout of six at HLA A, B, DR) renal transplants [6, 15].
The advent of rHuEPO treatment does not necessarily graft loss from such causes after 1991.
prevent the ability of transplant physicians to take advan-
tage of the “transfusion effect.” On the contrary, it may
ERYTHROPOIETIN AND ANEMIA
actually facilitate it by eliminating random transfusion POST-TRANSPLANT
and allowing the elective transfusion of a limited number
Several studies have assessed the recovery of endoge-of blood units over an interval of time sufficient to allow
nous erythropoietin secretion and the impact of this onthe careful screening of patients for the development of
recovery from anemia in the early post-transplant periodallosensitization.
[20–23]. Both Brown et al [20] and Sun et al [21] reported
that an initial early peak of erythropoietin occurs in
IMPACT OF PRIOR rHuEPO THERAPY the first 24 hours after transplantation, particularly in
ON TRANSPLANT OUTCOME patients with initial nonfunction. This is not associated
with erythropoiesis and is transient. A later, smaller, andThe issue of the impact of prior rHuEPO on transplant
outcome has been the subject of several studies, which more sustained peak occurs after the first week post-
transplant and is associated with the subsequent onsetare mostly retrospective in nature [16–18]. It has been
suggested that a higher hematocrit at the time of trans- of erythropoiesis and recovery of anemia over the next
two to three months. In patients with nonrenal anemia,plantation may have an adverse impact on intrarenal
blood flow during rewarming and that this problem may there is a clear inverse correlation between serum eryth-
ropoietin concentration and hemoglobin, that is, as he-be further aggravated by pretransplant hemodialysis and
ultrafiltration, which may further increase hematocrit. moglobin falls erythropoietin rises [24]. Patients with
renal anemia, in contrast, have been shown to display theSchmidt et al, in a retrospective study of patients trans-
planted at a single center between 1985 and 1991, found opposite relationship so that hemoglobin levels correlate
positively with (diminished) erythropoietin concentra-that both delayed graft function and primary nonfunc-
tion of renal allografts were significantly more common tions [25]. Besarab et al have shown that, following the
initial ineffective erythropoietin peak, the inverse rela-in patients with hematocrits of more than 30% compared
with patients with hematocrits of less than 30% [16]. tionship between serum erythropoietin concentrations
and hemoglobin is restored from day 30 post-transplantOnly a minority of the 244 patients studied had received
rHuEPO. Actuarial graft survival was not significantly onward, indicating a restoration of negative feedback
control [25].different at one, two, or three years for patients with or
without delayed graft function. Linde et al in a case A number of factors have been suggested as influenc-
ing the recovery of anemia after renal transplant, includ-control study of 26 allograft recipients treated with
rHuEPO were unable to discern any impact of treatment ing the development of initial nonfunction, acute rejec-
tion, intercurrent illness, and iron deficiency. In addition,prior to transplant on outcome [17]. Vasquez and Pollack
evaluated the effect of prior rHuEPO therapy on the up to 10% or more of renal transplant recipients develop
erythrocytosis that seems to result, at least in part, fromincidence of delayed graft function in 120 consecutive
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either hyperresponsiveness of the bone marrow to en- ceiving rHuEPO. However, many studies suggest that
ferritin may no longer be regarded as the best guidedogenous erythropoietin or the failure of negative feed-
back to cut off erythropoietin production. to available iron stores in renal failure, especially dur-
ing treatment of end-stage renal disease patients withBesarab et al reported that the onset of acute rejection
within the first month after renal transplant completely rHuEPO [30–32]. This has prompted a search for more
reliable indicators of functional iron deficiency to iden-abrogates the erythropoietic response until such time as
the rejection is successfully treated [25]. The onset of tify patients who require iron supplementation prior to
rHuEPO therapy. Few of these indicators, such as freeerythropoiesis has also been found to be critically depen-
dent on the presence of satisfactory graft function. Both erythrocyte protoporphyrin [33] or reticulocyte matura-
tion index [29], are routinely available to clinicians. Mostresumption of erythropoietin secretion, following the
initial ineffective peak, and reticulocytosis do not occur clinicians thus continue to rely on ferritin, despite its
limitations, and transferrin saturation as indicators ofuntil graft function occurs. Jeffrey et al found that eryth-
ropoietin concentrations were low and did not cor- iron status. In general, a transferrin saturation of less
than 20% and/or ferritin of less than 100 ng/ml indicaterespond to the degree of anemia pretransplant [26].
Compared with serum erythropoietin concentrations in a high likelihood of functional iron deficiency during
rHuEPO therapy and a probable need for iron supple-patients with nonrenal anemias, erythropoietin levels in
dialysis patients were only 22% of those expected for mentation during treatment [30, 34]. A serum ferritin of
less than 30 ng/ml is still regarded by most physicians asthe degree of anemia. However, following transplant,
there was a gradual increase in the serum erythropoietin indicative of absolute iron deficiency and as an indication
for iron supplementation prior to or concomitantly withconcentration to 100% of the expected level by 16 weeks
after transplant. In patients with excellent graft function, rHuEPO [30].
Teruel et al evaluated changes in serum ferritin con-serum erythropoietin concentrations reached the ex-
pected levels by 10 weeks. In contrast, patients with centration during anemia recovery after renal transplant
[35]. They reported that, whatever the initial value was,delayed or impaired graft function achieved only 75% of
serum ferritins tended to fall in the early post-transplanttheir expected serum erythropoietin concentration and
period and normalize by about 36-months post-trans-remained significantly anemic.
plant. Approximately one third of patients developedSeveral authors have reported that the serum concen-
low ferritin following transplant associated with persis-tration of soluble transferrin receptor (sTfR) rises prior
tent anemia. A prompt response to oral iron supplemen-to the development of reticulocytosis in the post-trans-
tation was noted. Patients with low baseline ferritinplant period, thus acting as an excellent early indicator
(mean 22.9 ng/ml) were more frequently anemic duringof marrow responsiveness [27, 28]. Elevated sTfR con-
the first year post-transplant than those with normal orcentrations have been reported in some patients with
high pretransplant serum ferritin. Among patients withpost-transplant erythrocytosis, suggesting that a defec-
low serum ferritin, anemia correction was more rapidtive feedback of the EPO release exists [27]. Similarly,
in those given supplemental iron, despite no significantthe reticulocyte maturity index, which indirectly mea-
change in serum ferritin, but the absolute level of anemiasures reticulocyte RNA and provides a measure of red
correction achieved was the same in supplemented andblood cell maturity, was reported to be a sensitive early
nonsupplemented patients.predictor of erythropoiesis following renal transplant
Moore et al, in a prospective study, found that almost[29]. Neither of these tests is readily available in routine
50% of allograft recipients had evidence of iron defi-clinical practice so that their utility in providing early
ciency by day 14 after renal transplantation [36]. Patientswarning of erythropoietic failure post-transplant is likely
identified as iron deficient were randomized to receiveto be limited.
iron supplementation (ferrous fumarate 200 mg/day) or
no therapy, whereas iron-replete patients received no
IRON METABOLISM FOLLOWING supplemental iron. Iron supplementation was able to
RENAL TRANSPLANT support erythropoiesis and prevent the later develop-
Although a great deal is known about iron metabolism ment of absolute iron deficiency. In contrast, the nonsup-
and iron requirements in hemodialysis patients, there are plemented patients remained iron deficient and anemic
comparatively few data concerning iron metabolism in at six months (mean ferritin 23 6 25 ng/ml; hematocrit
renal-transplant recipients. The introduction of rHuEPO 0.36 6 0.2), whereas the patients initially felt to have
into clinical practice has altered our thinking about the adequate iron stores had experienced a decline in ferritin
assessment of adequate iron stores. It used to be thought and transferrin and remained significantly more anemic
that serum ferritin, which correlates well with stainable than the iron-supplemented patients [36]. This study sug-
marrow iron in renal failure patients, was an adequate gests that absolute or relative iron deficiency develops in
a majority of patients following renal transplant. Possibleguide to overall iron stores in renal failure patients re-
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reasons for this may include blood loss at transplant, adverse event was a significant increase in diastolic blood
frequent blood sampling, use of marrow suppressant pressure, requiring an increase in antihypertensive drugs
drugs, and prior rHuEPO use, with consequent high iron for correction. Twelve of the 40 patients required initia-
demands. Moore et al do not indicate whether their tion of dialysis prior to the planned 24 weeks of rHuEPO
patients had received rHuEPO prior to renal transplant, therapy. These patients had significantly worse baseline
but given they were transplanted at a major United hemoglobin and renal function than patients who com-
States center during a time when more than 80% of pleted 24 weeks of therapy without the requirement for
hemodialysis patients were receiving rHuEPO, it is prob- dialysis. The previously mentioned studies suggest that
able that the majority had received this prior to trans- rHuEPO may be an effective treatment for the anemia
plant. The mean pretransplant hematocrit of 0.28 to 0.30 of chronic allograft dysfunction. The only risk appears
further suggests that most patients had received rHuEPO to be a worsening of hypertension, which requires an
prior to receiving their transplant. Intraoperative blood adjustment of antihypertensive medications. There ap-
loss, immunosuppressive protocol, and blood sampling pears to be little risk of hastening the rate of progression
were similar in all patients in this study, leaving the state to dialysis, with the caveat that patients with very poor
of relative iron deficiency induced by prior rHuEPO initial renal function may be at somewhat increased risk.
therapy as the most important factor in the subsequent Van Loo et al recently reported the results of a pro-
development of absolute iron deficiency. spective randomized study of the effects of rHuEPO
supplementation at the time of renal transplant on the
recovery of anemia [43]. Treatment in the immediate post-ERYTHROPOIETIN TREATMENT OF
operative period was associated with improved hemoglo-POST-TRANSPLANT ANEMIA
bin at four- and six-weeks post-transplantation, comparedAs in other forms of renal failure, chronic anemia is
with controls. This occurred despite greater intraoperativea feature of allograft dysfunction. However, potential
blood losses in the rHuEPO group and a higher fre-differences in etiology, such as the use of immunosup-
quency of postsurgical complications and requirement forpressives and a chronic inflammatory state, led to quite
gancyclovir. Blood transfusion requirements were signifi-reasonable speculation that rHuEPO might be less effec-
cantly less in patients receiving rHuEPO. Serum ferritintive as a treatment for anemia in renal allograft patients.
concentrations fell slightly in both patients and controls,Several studies have indicated that endogenous serum
despite iron supplementation. The dose of rHuEPO re-EPO concentrations are low in anemia related to allo-
quired to support erythropoiesis was approximately dou-graft failure, as in other forms of renal anemia, suggesting
ble that which had been required by the same patientsthat EPO deficiency is the dominant etiologic factor,
for maintenance of hemoglobin prior to transplant, indi-despite concerns to the contrary [37, 38].
cating a state of relative erythropoietin resistance. Fur-Yoshimura et al reported that i.v. rHuEPO was able
ther studies aimed at cost utility are required before ato correct anemia in a small number of patients with
recommendation can be made regarding perioperativechronic renal failure secondary to allograft dysfunction
use of rHuEPO in renal transplant patients.[39]. Jindal et al reported that a mean rHuEPO dose of
120 m/kg given subcutaneously once weekly was able to
increase hemoglobin from 68 6 5 g/liter to 96 6 6 g/liter POST-TRANSPLANT ERYTHROCYTOSIS
after some 15 weeks of therapy without any apparent
As many as 22% of patients have been reported toadverse effects on allograft function [40]. A modest in-
develop a sometimes marked erythrocytosis followingcrease in blood pressure, controlled by increases in anti-
renal transplantation [44–47]. In some cases, polycythe-hypertensive drugs, was the only significant adverse
mia is secondary to volume contraction from diureticevent. Traindl et al reported results similar to those of
use or glycosuria, but in others, there is a true increaseJindal with regard to efficacy and blood pressure. Mean
in red cell mass. In some patients, a clear-cut secondaryserum creatinine increased significantly during three
cause such as renal artery stenosis, cystic kidney disease,months of rHuEPO therapy, but no increased rate of
smoking, or polycythemia rubra vera can be identified,return to dialysis was apparent [40]. Traindl et al re-
whereas in others, there is no apparent cause. The diag-ported similar results in a group of 37 patients with mod-
nosis of true polycythemia requires isotopic determina-erate-to-severe chronic allograft failure (mean baseline
tion of red cell mass and plasma volume to exclude vol-creatinine 4.23 6 1.82 mg/dl) [41].
ume contraction [48]. The variable incidence of thisMuirhead et al in a study of approximately 40 patients
condition reported in the literature is the result of vari-with chronic renal allograft dysfunction reported that
ability in the criteria used to define the condition eitherdose requirements and clinical response, including im-
in terms of hematocrit or red cell volume. When a strictprovements in quality of life, were similar to those re-
ported in hemodialysis patients [42]. Again, the main definition based on a true increase in red cell mass is used,
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the incidence of post-transplant erythrocytosis seems to globin in post-transplant erythrocytosis indicates a more
direct role for angiotensin II in the pathogenesis of thisbe approximately 12%.
A number of factors have been reported to be associ- condition [56]. Potential mechanisms include a direct
role for angiotensin II on stem cell function or indirectated with an increased risk of erythrocytosis, including
male gender, absence of rejection in the early post-trans- effects mediated either through reduction in erythropoi-
etin production or through stimulation of cytokines, forplant period, and diabetes as initial renal disease. Kessler
et al noted in a prospective study of 81 consecutive allo- example, tumor necrosis factor a (TNF-a), in the marrow
[48]. Several reports have indicated that serum EPOgraft recipients that the 22.2% of patients who developed
true increase in red cell mass were more frequently male, concentrations are diminished during either ACE inhibi-
tor or losartan treatment, whereas there are experimen-had lower serum ferritins, were more frequently pre-
scribed iron supplements, and had required less time to tal data that indicate that angiotensin II plays a key role
in cytokine production in a variety of tissues. Excessivecorrect their anemia post-transplant than age- and sex-
matched controls [44]. Sumrani et al found true polycy- production of TNF-a has been implicated previously as
a key factor in the EPO resistance that accompaniesthemia in 8.1% (25 of 307) of their patients [46]. Again,
polycythemia was much more common in males and infection or chronic inflammation [57].
diabetics and occurred among patients with excellent
graft function who had experienced little or no early
SUMMARY
rejection. Sixteen of the 25 who became polycythemic
Although the introduction of rHuEPO into clinicalhad pretransplant hematocrits in excess of 30%. Kessler
practice has had a profound effect on the managementet al also noted a trend toward a higher hemoglobin and
of patients with renal anemia, the implications for renalless frequent need for rHuEPO therapy pretransplant
allograft patients are only now beginning to be clarified.in patients who later developed polycythemia [44].
Management of renal anemia with rHuEPO has allowedPost-transplant erythrocytosis is not a benign condi-
a substantial reduction in blood transfusion in patientstion. Several authors have reported an increased risk
awaiting transplant, with an accompanying decline inof thromboembolic events in addition to symptoms of
both the frequency and severity of allosensitization. Thehyperviscosity such as headache and dizziness [46, 47].
impact of this decrease sensitization on allograft out-Until recently, repeated phlebotomy was the most widely
come is currently unknown. Despite fears to the contrary,recommended treatment for post-transplant erythro-
patients treated with rHuEPO prior to transplant do notcytosis [46, 47, 49]. Although phlebotomy is certainly
appear to be at increased risk of graft loss from vascularsuccessful in reducing hematocrit temporarily, it may not
thrombosis and, despite a significantly increased risk ofsignificantly alter the risk of thromboembolic complica-
initial nonfunction, do not have inferior short or long-tions and is, in any event, inconvenient for the patient.
term graft survival.Theophylline has been shown to reduce polycythemia
Anemia is a frequent problem in the early post-trans-in chronic pulmonary disease [50] and has been shown
plant period. Prior rHuEPO therapy, with exhaustion ofto be effective in reducing hematocrit in post-transplant
available iron stores, may play a key role. Conventionalpolycythemia [51]. Theophylline is a nonselective antag-
markers of iron deficiency, such a serum ferritin or trans-onist of adenylate cyclase and most likely inhibits eryth-
ferrin saturation, can predict patients at risk, and earlyropoiesis through a reduction in adenosine-mediated
iron supplementation is effective in mitigating the ane-stimulation of erythropoietin secretion. However, the
mia. Other markers of iron deficiency, such as reticulo-use of theophylline in transplant patients is limited by
cyte maturity index or serum sTfR, may provide earlytoxicity, and it is unsuitable for long-term treatment.
warning of impending iron deficiency but are less suitableAngiotensin-converting enzyme (ACE) inhibitors have
for routine clinical use. The anemia that accompaniesrecently been shown to reduce hematocrit in both hemo-
chronic allograft failure appears to respond in a mannerdialysis and renal transplant patients being treated for
identical to that of other end-stage renal disease popula-hypertension [52]. Clinical trials have further indicated
tions, with no appreciable risks other than a manageablethat such drugs are effective in reducing hematocrit in
increase in blood pressure. Recent insights into thepatients with post-transplant erythrocytosis [53, 54]. The
pathogenesis of post-transplant erythrocytosis empha-exact mechanism whereby ACE inhibitors are effective
size the key role of angiotensin II. Risk factors, includingin reducing hematocrit is currently unknown. It has been
male sex, absence of early acute rejection, and priorsuggested that ACE may play a facilitative role in eryth-
rHuEPO therapy have been identified, although theirropoiesis by promoting hydrolysis of Ac-SDKP, a pep-
precise relationships to the problem remain unresolved.tide with known effects on regulation of erythropoiesis
Angiotensin converting enzyme inhibition and angioten-[55]. However, the recent observation that treatment
sin II type 1 receptor blockade have both been shown inwith losartan, a selective antagonist of the angiotensin
II type 1 receptor, is equally effective in reducing hemo- clinical studies to be effective treatment for this problem.
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